KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) Equity Ratio (2016 - 2025)

Jazz Pharmaceuticals has reported Equity Ratio over the past 16 years, most recently at 0.37 for Q4 2025.

  • Quarterly results put Equity Ratio at 0.37 for Q4 2025, up 8.69% from a year ago — trailing twelve months through Dec 2025 was 0.37 (up 8.69% YoY), and the annual figure for FY2025 was 0.37, up 8.69%.
  • Equity Ratio for Q4 2025 was 0.37 at Jazz Pharmaceuticals, up from 0.35 in the prior quarter.
  • Over the last five years, Equity Ratio for JAZZ hit a ceiling of 0.56 in Q1 2021 and a floor of 0.26 in Q3 2022.
  • Median Equity Ratio over the past 5 years was 0.32 (2024), compared with a mean of 0.33.
  • Biggest five-year swings in Equity Ratio: tumbled 45.45% in 2022 and later increased 17.81% in 2023.
  • Jazz Pharmaceuticals' Equity Ratio stood at 0.32 in 2021, then fell by 11.67% to 0.28 in 2022, then rose by 15.17% to 0.33 in 2023, then grew by 3.9% to 0.34 in 2024, then grew by 8.69% to 0.37 in 2025.
  • The last three reported values for Equity Ratio were 0.37 (Q4 2025), 0.35 (Q3 2025), and 0.34 (Q2 2025) per Business Quant data.